BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2574908)

  • 1. The clinical utility and safety of omeprazole.
    Walan A
    Scand J Gastroenterol Suppl; 1989; 166():140-4; discussion 145. PubMed ID: 2574908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    McTavish D; Buckley MM; Heel RC
    Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
    Walan A
    Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic achlorhydria: for which diseases, when and for how long?].
    Koop H; Arnold R
    Dtsch Med Wochenschr; 1988 Mar; 113(13):516-8. PubMed ID: 2894969
    [No Abstract]   [Full Text] [Related]  

  • 10. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the H+/K+-adenosine triphosphatase inhibitor omeprazole in peptic ulcer.
    de Bruijne JW; Snel P; Lamers CB
    Digestion; 1989; 44 Suppl 1():25-30. PubMed ID: 2691308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
    Chelvam P; Wong EC
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G; Sabbatini F; Mazzacca G
    Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
    [No Abstract]   [Full Text] [Related]  

  • 20. Omeprazole.
    Walan A
    Baillieres Clin Gastroenterol; 1988 Jul; 2(3):629-40. PubMed ID: 3048454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.